Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avandia Re-Adjudication Might Result In “Refreshing” Restricted Distribution Roll Back

This article was originally published in The Pink Sheet Daily

Executive Summary

More than half of a 26-member advisory committee supports eliminating or easing the REMS for GSK’s diabetes drug, but the spilt vote and high-profile of the product’s safety issues suggest that FDA is unlikely to modify Avandia’s risk management.

You may also be interested in...



Avandia Panel Wants Another Trial: Pipe Dream Or Post-market Benchmark?

Designed with complex, multi-variate statistics, an observational trial could determine the CV risk of rosiglitazone compared to other diabetes drugs, an advisory committee member suggests during the latest assessment of Avandia.

Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner

A re-adjudication of cardiovascular events in the RECORD trial reassured members of a June 5-6 advisory committee that the study findings are reliable, but did not erase uncertainties about CV risk associated with rosiglitazone.

IMS Health’s Yan Shangjun On China’s Changing Diabetes Market: An Interview With PharmAsia News

IMS Health Inc. Pharma Insight Principal Yan Shangjun sits down with PharmAsia News to talk about the evolution of China’s diabetes market and how opinions of Chinese doctors affect the market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel